AMIODARONE HYDROCHLORIDE INJECTION SOLUTION

Land: Canada

Sprog: engelsk

Kilde: Health Canada

Aktiv bestanddel:

AMIODARONE HYDROCHLORIDE

Tilgængelig fra:

MYLAN PHARMACEUTICALS ULC

ATC-kode:

C01BD01

INN (International Name):

AMIODARONE

Dosering:

50MG

Lægemiddelform:

SOLUTION

Sammensætning:

AMIODARONE HYDROCHLORIDE 50MG

Indgivelsesvej:

INTRAVENOUS

Enheder i pakken:

10X3ML

Recept type:

Prescription

Terapeutisk område:

CLASS III ANTIARRYTHMICS

Produkt oversigt:

Active ingredient group (AIG) number: 0118593002; AHFS:

Autorisation status:

CANCELLED POST MARKET

Autorisation dato:

2016-07-06

Produktets egenskaber

_Amiodarone Hydrochloride Injection _
_ _
_Page 1 of 58_
_ _
PRODUCT MONOGRAPH
PR AMIODARONE HYDROCHLORIDE INJECTION
(Amiodarone Sterile Concentrate, BP)
50 mg/mL
Antiarrhythmic Agent
Mylan Pharmaceuticals ULC
85 Advance Road
Etobicoke, ON
M8Z 2S6
Submission Control No: 193735
Date of Revision: May 3, 2016
_Amiodarone Hydrochloride Injection _
_ _
_Page 2 of 58_
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................. 3
SUMMARY PRODUCT INFORMATION
.....................................................................................
3
INDICATIONS AND CLINICAL USE
...........................................................................................
3
CONTRAINDICATIONS
................................................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................................
4
ADVERSE REACTIONS
..............................................................................................................
14
DRUG INTERACTIONS
...............................................................................................................
17
DOSAGE AND ADMINISTRATION
...........................................................................................
21
OVERDOSAGE
.............................................................................................................................
24
ACTION AND CLINICAL PHARMACOLOGY
.........................................................................
25
STORAGE AND STABILITY
......................................................................................................
28
SPECIAL HANDLING INSTRUCTIONS
....................................................................................
28
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................................... 28
PART II: SCIENTIFIC INFORMATION
..............................................